Report Detail
Primary Sclerosing Cholangitis - Pipeline Review, H2 2019
- RnM3784273 |
- 26 September, 2019 |
- Global |
- 134 Pages |
- Global Markets Direct |
- Pharma & Healthcare
Primary Sclerosing Cholangitis - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 7, 4, 1, 11 and 1 respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis - Overview
Primary Sclerosing Cholangitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Sclerosing Cholangitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Gilead Sciences Inc
Immunic Inc
Intercept Pharmaceuticals Inc
Morphic Holding Inc
NGM Biopharmaceuticals Inc
Nyrada Inc
Pliant Therapeutics Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Sirnaomics Inc
Takeda Pharmaceutical Co Ltd
Primary Sclerosing Cholangitis - Drug Profiles
berberine ursodeoxycholate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Liver Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cilofexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMU-838 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odevixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1561 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-74809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QBT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QBT-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha 5 and Beta 6 for Non-Alcoholic Steatohepatitis and Primary Sclerosing Cholangitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Sclerosing Cholangitis - Dormant Projects
Primary Sclerosing Cholangitis - Discontinued Products
Primary Sclerosing Cholangitis - Product Development Milestones
Featured News & Press Releases
Aug 12, 2019: Immunic, announces first patient enrolled in investigator-sponsored proof-of-concept clinical trial of IMU-838 for the treatment of patients with primary sclerosing cholangitis
Jun 28, 2019: Pliant Therapeutics completes trial of PLN-74809 to treat in IPF
Jun 18, 2019: CymaBay Therapeutics announces IND to commence a clinical study of Seladelpar to treat primary sclerosing cholangitis
Apr 08, 2019: NGM Bio announces presentation of abstracts on NGM282 at The International Liver Congress 2019
Apr 08, 2019: Sirnaomics to present at World Orphan Drug Congress 2019
Apr 08, 2019: Clinical trial investigates Orbsen Therapeutics ORBCEL-C immunotherapy as treatment for two autoimmune liver diseases
Feb 15, 2019: CymaBay Therapeutics announces seladelpar granted breakthrough therapy designation by the FDA for the treatment of primary biliary cholangitis
Jan 03, 2019: Pliant Therapeutics initiates phase 1 clinical study of PLN-74809
Nov 20, 2018: Pliant Therapeutics receives FDA orphan drug designation for lead program PLN-74809 in primary sclerosing cholangitis
Nov 09, 2018: Pliant Therapeutics presents preclinical data on integrin inhibitors at The Liver Meeting 2018
Nov 09, 2018: Gilead announces positive phase 2 results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting 2018
Oct 11, 2018: Gilead to present data on Primary Sclerosing Cholangitis drug candidate GS-9674 at The Liver Meeting 2018
Oct 03, 2018: HighTide Therapeutics presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day
Sep 27, 2018: HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Primary Sclerosing Cholangitis
Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Summary:
Get latest Market Research Reports on Primary Sclerosing Cholangitis. Industry analysis & Market Report on Primary Sclerosing Cholangitis is a syndicated market report, published as Primary Sclerosing Cholangitis - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Primary Sclerosing Cholangitis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
